Peptide library
Dulaglutide: evidence profile
Approved product · Randomized evidence
Read each statement within its named product, route and evidence scope. The reading exercise below helps you examine a claim; it does not choose care.
Evidence record
- Product and route
- Subcutaneous injection.
- Approval scope
- Trulicity: specified type 2 diabetes populations.
- Mechanism
- GLP-1 receptor agonist fusion protein.
- Evidence
- Randomized studies.
- Limits
- No weight-management indication.
- Safety context
- Not recommended for severe gastroparesis.
A reading exercise
When a dulaglutide discussion uses a category, look for the measurement and cutoff behind the label. Sketch a scale with the boundary marked, using the document's own unit. Place two hypothetical values close to the boundary, one on each side, and consider what the category names reveal about their actual distance apart. Check how the rule handles a value exactly on the boundary. Keep the original values beside their assigned categories rather than replacing them with labels alone. This exercise asks how a classification summarizes a measurement; it does not ask you to apply a health label to yourself.
Questions to take away
- Which measured value and boundary determine the category used in this passage?
- How would the stated rule classify a value exactly on the boundary?
- What difference between the hypothetical values disappears when only category names remain?
Sources
The dates below identify each source check. Publication of this page does not mean every source was checked again.